The International Journal of Tuberculosis and Lung Disease

Working Alliance for TB Drug Development, Cape Town, South Africa, February 8th, 2000 [Declaration]
pp. 489-490(2)
Author: The Working Alliance for TB Drug Development

Pyrazinamide is not active against Mycobacterium tuberculosis residing in cultured human monocyte-derived macrophages [Unresolved issues]
pp. 491-495(5)
Authors: Heifets, L.; Higgins, M.; Simon, B.

Patient and disease characteristics, and outcome of treatment defaulters from the Singapore TB control unit—a one-year retrospective survey
pp. 496-503(8)
Authors: Chee, C. B. E.; Boudville, I. C.; Chan, S. P.; Zee, Y. K.; Wang, Y. T.

Twenty-five years of tuberculosis in a French university hospital: a laboratory perspective
pp. 504-512(9)
Authors: Robert, J.; Trystram, D.; Truffot-Pernot, C.; Cambau, E.; Jarlier, V.; Grosset, J.

Trial-of-antibiotic algorithm for the diagnosis of tuberculosis in a district hospital in a developing country with high HIV prevalence
pp. 513-518(6)
Authors: Wilkinson, D.; Newman, W.; Reid, A.; Squire, S. B.; Sturm, A. W.; Gilks, C. F.

HIV testing among tuberculosis patients in the era of antiretroviral therapy: a population-based study in Brazil
pp. 519-527(9)
Authors: DeRiemer, K.; Soares, E. C. C.; Dias, S. M. O.; Cavalcante, S. C.

Quantitative sputum bacillary load during rifampin-containing short course chemotherapy in human immunodeficiency virus-infected and non-infected adults with pulmonary tuberculosis
pp. 528-536(9)
Authors: Joloba, M. L.; Johnson, J. L.; Namale, A.; Morrissey, A.; Assegghai, A. E.; Mugerwa, R. D.; Ellner, J. J.; Eisenach, K. D.

Human immunodeficiency virus-related tuberculosis and primary drug resistance in Bangkok, Thailand
pp. 537-543(7)
Authors: Punnotok, J.; Shaffer, N.; Naiwatanakul, T.; Pumprueg, U.; Subhannachart, P.; Ittiravivongs, A.; Chuchotthaworn, C.; Ponglertnapagorn, P.; Chantharojwong, N.; Young, N. L.; Limpakarnjanarat, K.; Mastro, T. D.

Treatment monitoring and prevalence of drug resistance in tuberculosis patients in Tehran
pp. 544-549(6)
Authors: Bahrmand, A. R.; Velayati, A. A.; Bakayev, V. V.

A randomised controlled trial of lay health workers as direct observers for treatment of tuberculosis
pp. 550-554(5)
Authors: Zwarenstein, M.; Schoeman, J. H.; Vundule, C.; Lombard, C. J.; Tatley, M.

Effect of anti-tuberculosis treatment on the tuberculin interferon-γ response in tuberculin skin test (TST) positive health care workers and patients with tuberculosis
pp. 555-561(7)
Authors: Stuart, R. L.; Olden, D.; Johnson, P. D. R.; Forbes, A.; Bradley, P. M.; Rothel, J. S.; Grayson, M. L.

Antibody response to culture filtrate antigens of Mycobacterium tuberculosis during and after treatment of tuberculosis patients
pp. 562-569(8)
Authors: Imaz, M. S.; Zerbini, E.

Efficacy of common antiseptics against mycobacteria
pp. 570-576(7)
Authors: Rikimaru, T.; Kondo, M.; Kondo, S.; Oizumi, K.

3′UTR polymorphisms in the NRAMP1 gene are associated with susceptibility to tuberculosis in Koreans
pp. 577-580(4)
Authors: Ryu, S.; Park, Y.-K.; Bai, G.-H.; Kim, S.-J.; Park, S.-N.; Kang, S.

Time between sputum examination and treatment in patients with smear-negative pulmonary tuberculosis
pp. 581-583(3)
Authors: Salaniponi, F. M. L.; Gausi, F.; Kwanjana, J. H.; Harries, A. D.

DNA fingerprinting of a national sample of Mycobacterium tuberculosis isolates, Botswana, 1995–1996
pp. 584-587(4)
Authors: Lockman, S.; Sheppard, J. D.; Mwasekaga, M.; Kenyon, T. A.; Binkin, N. J.; Braden, C. R.; Woodley, C. L.; Rumisha, D. W.; Tappero, J. W.

Study of the in vitro susceptibility of M. tuberculosis to ofloxacin in Spain
pp. 588-591(4)
Authors: Casal, M.; Ruiz, P.; Herreras, A.; Spanish Study Group of M. tuberculosis resistance, Spain